The role played by oral antioxidant therapies in preventing and treating preeclampsia: An updated meta-analysis.

Published
May 29, 2023
Journal
Nutrition, metabolism, and cardiovascular diseases : NMCD
PICOID
fe1ec7bf
DOI
Citations
1
Keywords
Antioxidant, Oral administration, Oxidative stress, Pregnant women
Copyright
Copyright © 2023 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
Patients/Population/Participants

pregnant women

Intervention

oral antioxidant therapies

Comparison

control groups

Outcome

incidence of preeclampsia

Abstract

P
I
C
O

Performing an up-to-date meta-analysis of oral antioxidant therapies and determining whether they are effective in preventing and/or treating preeclampsia (PE). Search was performed in PubMed, CENTRAL, LILACS, Web of Science, and ScienceDirect databases. The risk of bias was assessed based on using Cochrane Collaboration's tool. A funnel plot was created, and Egger's and Peter's test was carried out to assess publication bias in the primary outcome of prevention studies. The overall quality of the evidence was assessed based on using the Grading of Recommendations Assessment, Developing and Evaluation (GRADE) tool; a formal protocol was published in the PROSPERO database (registration number CRD42022348992). In total, 32 studies were taken into consideration for analysis purposes; 22 studies focused on investigating preeclampsia prevention methods, whereas 10 focused on its treatment. Significant results associated with the incidence of preeclampsia were observed in prevention studies comprising 11,198 subjects and 1106 events in the control groups, as well as 11,156 subjects and 1048 events in the intervention groups (relative risk [RR]: 0.86, 95% confidence interval [CI]: [0.75, 0.99], P = 0.03; I Antioxidant therapy has shown beneficial effects on preeclampsia prevention; moreover, the positive impact of this therapy on intrauterine growth restriction was observed during the disease treatment.

Similar article map

CEO: Hwi-yeol YunCOO: Jung-woo ChaeCTO: Sangkeun Jung
Location: 204, W6, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon, Republic of Korea
Tel: 042-821-7328E-mail: webmaster@lilac-co.kr
Copyright © 2024 by LiLac. All Rights Reserved.